13 completed, 5 active not recruiting, 3 terminated, 2 withdrawn. 26 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 13, Active not recruiting 5, Terminated 3, Withdrawn 2, Recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 8 | Active not recruiting 3, Completed 3, Terminated 1, Withdrawn 1 |
Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation - Plasma Cell Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2024-01-27 | 2024-01-31 | |
| CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma Infusion of CS1 CAR-T cell product - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2023-07-05 | 2026-09-18 |
| Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) - Multiple Myeloma, Plasma Cell Myeloma | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 20 | 2023-06-16 | 2026-09-16 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 49 | 2022-08-11 | 2026-10-16 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Venetoclax, Fludarabine, Cyclophosphamide - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1 | Phase 1 | Unknown | Melbourne Health | 18 | 2022-06-08 | 2023-08-01 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 5 | 2021-06-03 | 2025-05-18 |
| Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2019-10-09 | 2025-05-01 |
| First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma SAR442085 - Plasma Cell Myeloma | Phase 1 | Completed | Sanofi | 37 | 2019-08-19 | 2025-09-12 |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2019-08-08 | 2026-06-11 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Natural Killer (NK) Cells, ALT803 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Brenda Cooper, MD | 14 | 2018-05-22 | 2023-02-21 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Isatuximab SAR650984, Cemiplimab REGN2810 - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Sanofi | 109 | 2018-02-21 | 2024-06-14 |
| Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma Daratumumab, Imaging Agent, Positron Emission Tomography - Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma | Phase 1 | Completed | City of Hope Medical Center | 12 | 2018-02-21 | 2024-03-12 |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2018-01-01 | 2017-12-13 | |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide - Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 18 | 2017-04-13 | 2026-05-15 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Anakinra, Dexamethasone, Laboratory Biomarker Analysis - Indolent Plasma Cell Myeloma, Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 14 | 2016-04-01 | 2020-03-25 |
| Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation lenalidomide, bortezomib, cyclophosphamide - Plasma Cell Myeloma | Phase 1 | Completed | Sanofi | 90 | 2015-09-30 | 2024-01-29 |
Showing 20 of 26. Sign in to see all of them.
Multiple Myeloma (26) · Lymphoma, Non-Hodgkin (7) · Leukemia, Myeloid, Acute (6) · Myelodysplastic Syndromes (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Anemia, Aplastic (3) · Myeloproliferative Disorders (3) · Graft vs Host Disease (2) · Rectal Neoplasms (2) · Smoldering Multiple Myeloma (2) · Amyloidosis (1) · Blast Crisis (1)
Blood Protein Disorders (26) · Cardiovascular Diseases (26) · Hematologic Diseases (26) · Hemic and Lymphatic Diseases (26) · Hemorrhagic Disorders (26) · Hemostatic Disorders (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Lymphoproliferative Disorders (26) · Neoplasms by Histologic Type (26) · Paraproteinemias (26) · Vascular Diseases (26) · Neoplasms (25) · Neoplasms, Plasma Cell (25) · Leukemia (8)
Cyclophosphamide (8) · Dexamethasone (8) · Lenalidomide (6) · Melphalan (6) · Calcium Dobesilate (5) · isatuximab (5) · Peripheral Blood Stem Cell Transplantation (4) · Whole-Body Irradiation (4) · auricularum (4) · dexamethasone 21-phosphate (4) · dexamethasone acetate (4) · fludarabine phosphate (4) · Bortezomib (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3)
Sanofi (6) · Mayo Clinic (4) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Roswell Park Cancer Institute (2) · Biomea Fusion Inc. (1) · Brenda Cooper, MD (1) · David Wald (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Melbourne Health (1) · Robert Flavell, MD, PhD (1) · University of Colorado, Denver (1)
United States (23) · France (4) · Spain (4) · Czechia (3) · Greece (3) · Italy (3) · Australia (2) · Brazil (1) · Canada (1) · China (1) · Germany (1) · Hungary (1) · Netherlands (1) · Taiwan (1)
Amrita Krishnan, MD (1) · Benjamin Tomlinson, MD (1) · Choon-Kee Lee, MD (1) · Damian Green (1) · Damian J. Green (1) · David Ritchie (1) · David Wald, MD, PhD (1) · George Somlo, MD (1) · Jens Hillengass, MD, PhD (1) · John Lust (1) · Junyuan Qi, MD (1) · Maureen Ross (1) · Prashant Kapoor, MD (1) · Qaiser Bashir (1)
PMID 33980831, PMID 28483761, PMID 30862646, PMID 32710011, PMID 33095874, PMID 34050260, PMID 34272304, PMID 35737873, PMID 37316728, PMID 38993150, PMID 42041169, PMID 42537695
2014 (1), 2017 (1), 2019 (1), P30CA015083 (1), P30CA015704 (1), R01CA205248 (1), R01CA271606 (1), R21CA155911 (1)